Pennsaid^® (1.5% w/w diclofenac sodium solution)

Pennsaid^®, the first medication based on the company's patented transcellular technology, is used to treat osteoarthritis pain and stiffness. The drug combines a proprietary carrier with diclofenac sodium, a leading nonsteroidal anti-inflammatory drug (NSAID), and delivers active ingredient through the skin directly to the pain site. After many clinical studies, Pennsaid^® lotion has not been linked to the problems often found with conventional NSAID treatment.

When used regularly, NSAID pills can cause numerous side effects. The most severe are ulcers and gastrointestinal bleeding, but they can also include blood pressure increases, dizziness, headache, depression and delayed stomach emptying.

With topically applied Pennsaid^®, the most common adverse reaction has been mild dryness or irritation at the application site. A recent equivalence study has also shown that Pennsaid^® works as well as the maximum daily dose of oral diclofenac, without provoking serious side effects..

Pennsaid^® is currently available in Canada, the United Kingdom, Italy, Greece, Portugal and the Caribbean. The Company has recently completed Phase III Clinical Trials for efficacy/safety and anticipate long-term safety trial results in February 2006. Nuvo expects to file an amended New Drug Application (NDA) for Pennsaid^® with the U.S. Food and Drug Administration (FDA) in mid 2006.

For any medical information inquiries on our products, please contact Medical Information Services at 1-888-398-3463 or email us at medinfo@nuvoresearch.com.